{Reference Type}: Case Reports
{Title}: Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series.
{Author}: Hochman MJ;Gerber GF;Imus PH;Ali SA;DeZern AE;
{Journal}: Leuk Res Rep
{Volume}: 22
{Issue}: 0
{Year}: 2024
暂无{DOI}: 10.1016/j.lrr.2024.100469
{Abstract}: Both clonal plasma cell and myeloid disorders occur more frequently with age. Patients with concurrent clonal plasma cell and myeloid disorders (CPCMD) can present clinical and therapeutic challenges. In this single-institution cohort of patients with CPCMD (n = 18), we abstracted clinically relevant themes. A majority of patients (12/18) were treated with clone-directed therapies and three received treatment targeting both clones. Treatment of clones with targetable genetic lesions or those causing end-organ complications should be prioritized. Simultaneous treatment of both clones can be safe but is best done in a stepwise manner. Further study of patients with dual clonal processes is warranted.